Health Care [ 1/12 ] | Biotechnology [ 8/73 ]
NASDAQ | Common Stock
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors.
The company was incorporated in 2021 and is based in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 19, 25 | -9.10 Increased by +94.65% | -4.35 Decreased by -109.20% |
| Aug 22, 25 | -61.71 Increased by +79.59% | -6.21 Decreased by -893.72% |
| May 15, 25 | -31.80 Increased by +89.83% | -119.20 Increased by +73.32% |
| Feb 26, 25 | -17.49 Increased by +80.68% | - |
| Sep 30, 24 | -170.22 Decreased by -61.35% | - |
| Jun 30, 24 | -302.32 Increased by +27.98% | - |
| Mar 31, 24 | -312.74 Decreased by -119.75% | - |
| Dec 31, 23 | -90.54 Decreased by -905.28 K% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | N/A Decreased by N/A% | -11.51 M Decreased by -369.90% | - - |
| Jun 30, 25 | 0.00 Decreased by N/A% | -5.42 M Decreased by -135.57% | Decreased by N/A% - |
| Mar 31, 25 | 1.16 M Increased by +N/A% | -5.11 M Decreased by -1.71 K% | Decreased by -439.10% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -4.23 M Decreased by -1.17 K% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -2.45 M Decreased by -16.99% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | N/A Decreased by N/A% | -2.30 M Increased by +5.67% | - - |
| Dec 31, 23 | 0.00 Decreased by N/A% | -282.76 K Decreased by -7.65% | Decreased by N/A% - |
| Sep 30, 23 | 0.00 Decreased by N/A% | -334.03 K Decreased by -495.28% | Decreased by N/A% - |